Tsagiopoulou, Maria
Papakonstantinou, Nikos
Moysiadis, Theodoros
Mansouri, Larry
Ljungström, Viktor
Duran-Ferrer, Martí
Malousi, Andigoni
Queirós, Ana C.
Plevova, Karla
Bhoi, Sujata
Kollia, Panagoula
Oscier, David
Anagnostopoulos, Achilles
Trentin, Livio
Ritgen, Matthias
Pospisilova, Sarka
Stavroyianni, Niki
Ghia, Paolo
Martin-Subero, Jose I.
Pott, Christiane
Rosenquist, Richard
Stamatopoulos, Kostas http://orcid.org/0000-0001-8529-640X
Funding for this research was provided by:
European Hematology Association
Associazione Italiana per la Ricerca sul Cancro (21198)
Ministerstvo Školství, Mládeže a Tělovýchovy (CEITEC2020 LQ1601)
Horizon 2020 (AEGLE)
General Secretatiat for research and technology of Greece (KRIPIS)
ERA-NET TRANSCAN-2 JTC 2014, GCH-CLL (143)
MIUR-PRIN (2015ZMRFEA)
Swedish Cancer Society (Swedish Cancer Society)
Knut och Alice Wallenbergs Stiftelse (Knut och Alice Wallenbergs Stiftelse (SE))
Swedish Research Council (Swedish Research Council)
Radiumhemmets Forskningsfonder (Radiumhemmets Forskningsfonder)
Lion’s Cancer Research Foundation (Lion’s Cancer Research Foundation)
Marcus Borgström’s Foundatio (Marcus Borgström’s Foundatio)
Selander’s Foundation (Selander’s Foundation)
State of scholarships foundation of Greece (fellowship)
Article History
Received: 24 September 2019
Accepted: 19 November 2019
First Online: 2 December 2019
Ethics approval and consent to participate
: The study was approved by the local Ethics Review Committee for the Institute of Applied Biosciences/Centre for Research and Technology Hellas (Ref. No: ETH.COM-45).
: Not applicable.
: PG has received research funding from AbbVie, Gilead, Janssen, Novartis, and Sunesis. Has received honoraria from AbbVie, Acerta, BeiGene, Gilead, Janssen, Novartis, and Sunesis. RR has received honoraria from AbbVie, Janssen, Illumina, and Roche. KS received research support from Janssen Pharmaceuticals and Roche SA. All other authors declare no competing interests.